Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

NCT01806064 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

173

Enrollment

INDUSTRY

Sponsor class

Stopped The study did not meet endpoint.

Conditions

Renal Cell Carcinoma

Interventions

DRUG: TRC105 and Axitinib
DRUG: Axitinib

Sponsor

Tracon Pharmaceuticals Inc.